BIO139 vaccines
Order by
41 terms
Terms | Definitions |
|---|---|
 TETANUS: mode of transmission | contaminated wounds |
| TETANUS: efficacy | 80-90% |
| TETANUS: caused by | by tetanus toxoids |
| TETANUS | last for 10 yrs. 2 series shots (2,4,6) after-every 10 yrs. DTap: youngings, TDap: oldies |
| TETANUS: symptoms | spasms, jaw stiffness, neck stiffness, difficulty swallowing, abdominal stiffness, fever, sweating, elevated BP, rapid heartbeats. |
| DIPETHERIA: causal agent | corynebacterium diphtheriae, toxid |
| DIPETHERIA: symptoms | fatigue, fever, mild sore throat, probs swallowing, breathing probs |
| DIPETHERIA: mode of transmission | airborne, carrier (person to person) |
| DIPETHERIA: efficacy | 83% |
| DIPETHERIA: vaccine prep | conjugated toxoid |
| PERTUSSIS: causal agent | bordetella pertussis (whopping cough) |
| PERTUSSIS: symptoms | whooping, runny nose, cough, nasal congestion, sneezing, red-watery eyes, mild -high fever. |
| PERTUSSIS: mode of transformation | direct contact, airborne |
| PERTUSSIS: efficacy | not to great, not enough ppl are being vaccinated. |
| PERTUSSIS: vaccine prep | conjugated based toxoid |
| HPV: causal agent | papillomavirus |
| HPV: symptoms | warts and cancer |
| HPV: mode of transmission | person to person contact, prenatal |
| HPV: vaccine prep | subunit attach to toxoid rationale: mixture of HPV that cause genital warts/cervical cancer. 3 vaccines to immunity |
| HPV: efficacy of vaccine | 93% in women 75% in men |
| INFLUENZA: causal agent | RNA virus of the influenza virus |
| INFLUENZA:symptoms | high fever, aches, chills & sweats, fatigue & weakness, nasal congestion |
| INFLUENZA: mode of transmission | airborne, droplets, person to person contact |
| INFLUENZA: vaccine prep | influenza vaccine |
| INFLUENZA: efficacy | 80% in preventing death 65+ harder to make antibody=less effective |
| HAEMOPHILUS INFLUENZAE B (HiB): causal agent | bacterial agents |
| HAEMOPHILUS INFLUENZAE B (HiB): symptoms | include fever, vomiting and a stiff neck |
| HAEMOPHILUS INFLUENZAE B (HiB): mode of transmission | respiratory droplet spread |
| HAEMOPHILUS INFLUENZAE B (HiB): vaccine prep | conjugated vaccine, polysaccharide (PRP-T & PRP-OMP) |
| HAEMOPHILUS INFLUENZAE B (HiB): efficacy of vaccine | 59%-98% |
| MEASLES: causal agent | "measels virus" RNA virus- viral pathogens |
| MEASLES: symtpoms | fever, dry cough, runny nose, sore throat, inflamed eyes, skin rash, etc. |
| MEASLES: mode of transmission | airborne, respiratory route, direct contact |
| MUMPS: causal agent | RNA virus |
| MUMPS: symptoms | swollen, painful salivary glands on 1 or both sides of face, chewing/swallowing pains, fever, weak, fatigue |
| MUMPS: mode of transmission | droplet (nuclei, saliva, fomites), through respiratory route |
| RUBELLA: causal agent | rubella virus |
| RUBELLA: symptoms | mild fever, headache, stuffy/runny nose, inflamed-red eyes, fine pink rash, aching joints, enlarged-tender lymph nodes on face. |
| RUBELLA: mode of transmission | airborne, droplets shed from respiratory secretions of infected agent |
| MMR vaccine prep | live attenuated vaccine |
| MMR efficacy | 95% |
First Time Here?
Welcome to Quizlet, a fun, free place to study. Try these flashcards, find others to study, or make your own.